May 25, 2017
Participants in randomized control trials for nonalcoholic fatty liver disease had significantly different characteristics, such as age, BMI and sex, compared with patients in observational studies, according to a systematic review.
“Given the high prevalence of NAFLD, there is a need for effective therapies to prevent progression of disease and to treat established fibrosis. However, while many treatments have been trialed, few have shown categorical benefit in [nonalcoholic steatohepatitis],” Richard Parker, PhD, from the University of Birmingham, U.K., and colleagues wrote. “Poor external validity may promote ineffective treatments or, conversely, limit the acceptance of effective treatments. These data ... show that characteristics of individuals with NAFLD in [observational studies] differ from those included in [randomized control trials].”